For the Inventor, By the Inventor

Enter assignee name

New York, NY, United States of America

Synergy Pharmaceuticals, Inc.

USPTO Granted Patents = 34

% Expired Patents = 11.8

CIPO Patents = 11

EPO Patents = 13

Trademarks = 2

Forward Citations = 480

Loading Chart...

Loading Chart...

15 inventors (with patents filed for the assignee):

Kunwar Shailubhai (34 out of 51 patents)

Gary S Jacob (14 out of 33 patents)

Stephen Comiskey (8 out of 23 patents)

4. Rong Feng (7 out of 13 patents)

5. John Foss (5 out of 5 patents)

6. Gregory Nikiforovich (3 out of 4 patents)

7. Juncai Bai (2 out of 8 patents)

8. Ruoping Zhang (2 out of 8 patents)

9. Jun Jia (2 out of 7 patents)

10. Qiao Zhao (2 out of 10 patents)

11. Junfeng Zhou (2 out of 8 patents)

12. Guoqing Zhang (1 out of 9 patents)

13. Dennis Riff (1 out of 3 patents)

14. Patrick H Griffin (1 out of 4 patents)

15. Guoquing Zhang (1 out of 2 patents)

Core Competencies:

Guanylate Cyclase

Gastrointestinal Disorders

Agonists

Inflammation

Cancer

Cardiovascular Diseases

Hypercholesterolemia

Atherosclerosis

Gallstone

Obesity

Receptor Agonists

Formulations

34 patents: Sort by Forward Citations

1. 10238712 - Compositions useful for the treatment of gastrointestinal disorders (2019-03-26),

2. 10232011 - Formulations of guanylate cyclase C agonists and methods of use (2019-03-19),

3. 10118946 - Agonists of guanylate cyclase and their uses (2018-11-06),

4. 10034836 - Formulations of guanylate cyclase C agonists and methods of use (2018-07-31),

5. 10011637 - Ultra-pure agonists of guanylate cyclase C, method of making and using same (2018-07-03),

6. 9925231 - Formulations of guanylate cyclase C agonists and methods of use (2018-03-27),

7. 9920095 - Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders (2018-03-20),

8. 9919024 - Formulations of guanylate cyclase C agonists and methods of use (2018-03-20),

9. 9914752 - Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders (2018-03-13),

10. 9814752 - Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases (2017-11-14),

11. 9708367 - Agonists of guanylate cyclase and their uses (2017-07-18),

12. 9616097 - Formulations of guanylate cyclase C agonists and methods of use (2017-04-11),

13. 9610321 - Formulations of guanylate cyclase C agonists and methods of use (2017-04-04),

14. 9580471 - Process of preparing guanylate cyclase C agonists (2017-02-28),

15. 9545446 - Agonists of guanylate cyclase and their uses (2017-01-17),

Company Overview

Synergy Pharmaceuticals, Inc. is a biopharmaceutical company based in New York, specializing in the development of innovative therapies for gastrointestinal diseases. The company focuses on addressing unmet medical needs through its proprietary drug candidates, which target conditions such as chronic constipation and irritable bowel syndrome. With a commitment to advancing gastrointestinal health, Synergy Pharmaceuticals leverages its expertise in drug formulation and clinical research to bring new treatment options to patients.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

34 Patents

#261 in New York, NY

#601 in New York

#10,014 in US

#19,631 in the World

New York, NY, United States of America

Synergy Pharmaceuticals, Inc.

Forward Citations = 480

15 inventors:

Kunwar Shailubhai (34 out of 51 patents)

Gary S Jacob (14 out of 33 patents)

Stephen Comiskey (8 out of 23 patents)

4. Rong Feng (7 out of 13 patents)

5. John Foss (5 out of 5 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Synergy Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/synergy-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…